8 not yet recruiting. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Not yet recruiting 8 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Zoster Vaccination in Glioblastoma Patients Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination - Glioblastoma (GBM) | Phase 4 | Not yet recruiting | University Hospital, Essen | 230 | 2027-01-02 | 2026-04-23 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus) - Melanoma, Acral Melanoma | Phase 4 | Not yet recruiting | Peking University Cancer Hospital & Institute | 76 | 2026-10-01 | 2026-10-02 |
| Impact of Dysport on PMFF Donor Scar Abobotulinumtoxin-A, Control- Saline injection - Skin Cancer Excision Site, Basal Cell Carcinoma | Phase 4 | Not yet recruiting | Vanderbilt University Medical Center | 50 | 2026-09-14 | 2026-08-26 |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Irinotecan Hydrochloride Liposome Injection, 5-FU, LV - Neuroendocrine Carcinomas (NEC) | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | 45 | 2025-06-20 | 2025-06-11 |
| Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis Atorvastatin, Placebo - Atherosclerosis, Melanoma | Phase 4 | Not yet recruiting | Erasmus Medical Center | 140 | 2025-02-01 | 2025-01-22 |
| Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma Irinotecan liposomes combined with cisplatin/carboplatin - Neuroendocrine Tumors | Phase 4 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 20 | 2024-07-01 | 2024-07-03 |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. Naxitamab - Neuroblastoma | Phase 4 | Not yet recruiting | SciClone Pharmaceuticals | 62 | 2023-10-31 | 2023-09-21 |
Melanoma (4) · Atherosclerosis (1) · Carcinoma, Basal Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · Glioblastoma (1) · Neuroblastoma (1) · Neuroendocrine Tumors (1) · Skin Neoplasms (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Nerve Tissue (8) · Neuroendocrine Tumors (5) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Nevi and Melanomas (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Skin Neoplasms (3) · Carcinoma (2) · Neoplasms, Neuroepithelial (2) · Adenocarcinoma (1)
Atorvastatin (1) · Botulinum Toxins, Type A (1) · Carboplatin (1) · Cisplatin (1) · Fluorouracil (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Isotretinoin (1) · Nivolumab (1) · naxitamab (1) · relatlimab (1)
Beijing GoBroad Hospital (1) · Bristol-Myers Squibb (1) · Erasmus Medical Center (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Peking University Cancer Hospital & Institute (1) · SciClone Pharmaceuticals (1) · University Hospital, Essen (1) · Vanderbilt University Medical Center (1)
China (1) · India (1) · Netherlands (1) · United States (1)
EnXiao Li, PhD (1) · Jorie Versmissen, MD,PhD (1) · Shiayin F Yang, MD (1)